Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Multispecies synbiotic in people on hemodialysis

Official title: Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients

Run by Tungs' Taichung Metroharbour Hospital · NCT07461233 · Data updated 2026-11-12

This pilot study tests whether a multispecies synbiotic can alter gut microbes and reduce gut-derived toxins in adults on maintenance hemodialysis over 12 weeks.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorTungs' Taichung Metroharbour Hospital
Academic / other
Locations1 site (Taichung, Wuqi District)
StatusRecruiting
StartedMay 4, 2026
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedSeptember 25, 2026
Trial IDNCT07461233 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older on maintenance hemodialysis for at least 3 months, not using probiotics in the past month and without major exclusions such as active infections or major intestinal surgery.

Probably not a fit

Patients with active malignancy, advanced heart failure, liver disease, thyroid disorders, recent antibiotic use, or recent hospitalization may not experience benefit or may be excluded from analysis.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label pilot trial evaluating the effect of multispecies synbiotic supplementation on the gut microbiome, gut permeability markers, and circulating uremic toxins in adults receiving maintenance hemodialysis for at least 3 months. Participants will take the synbiotic for 12 weeks, with assessments of fecal microbiota composition and serum levels of uremic toxins such as indoxyl sulfate. The study aims to see if modulating the gut ecosystem can decrease systemic toxin burden and improve intestinal barrier integrity. The results will inform feasibility, tolerability, and potential signals of benefit for larger controlled studies. The trial is conducted at a single center in Taichung, Taiwan, led by Tungs' Taichung Metroharbour Hospital.

Why it matters

Potential benefit: If successful, participants might experience lower levels of gut-derived toxins and improved gut barrier function, which could translate into reduced inflammation and potential cardiovascular benefits.

How similar studies have gone: Previous small studies suggest gut-targeted therapies can influence toxin levels, but evidence for multispecies synbiotics in hemodialysis patients is limited and further confirmation is needed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months

Exclusion Criteria:

1. Use of probiotic supplements within the last month;
2. Hospitalization within the past month for acute infections or CKD-related complications;
3. History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);
4. Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;
5. Use of antibiotics or immunosuppressive therapy within the preceding three months.

Where it's running

  • Tungs' Taichung Metroharbour Hospital
    Taichung, Wuqi District, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.